Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 4Phase 1 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 10Breast 2Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Neoplasms 1Chemotherapy-Induced Febrile Neutropenia 1

Interventions

Epoetin Alfa 8ferric carboxymaltose 6epoetin beta 6Meropenem 6Ceftazidime 5Vancomycin 4Darbepoetin alfa 4apixaban 3Enoxaparin 3Ciprofloxacin 3Cefepime 3iron isomaltoside 1000 2ferrous sulfate 2ferrous fumarate 2Teicoplanin 2Radiotherapy 2Levofloxacin 2Filgrastim 2Dalteparin 2Cholecalciferol 2Aspirin 2Amikacin 2sotorasib 1posaconazole 1ferrous succinate 1ferric gluconate 1eltrombopag 1ceftolozane, tazobactam drug combination 1Vitamin B 12 1Vaccination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Granulocyte Colony-Stimulating Factor × Classical hematology × Clear all
NCT03823950 2020-03-13

Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients

University of Mississippi Medical Center

Phase 4 Unknown
150 enrolled
Classical hematology

Neoplasms, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡